Edwards Lifesciences Corporation $EW Shares Sold by Intech Investment Management LLC

Key Points

• Intech Investment Management LLC reduced its stake in Edwards Lifesciences by 54.7%, holding 77,244 shares valued at approximately $5.60 million following the sale of 93,151 shares.
• Edwards Lifesciences reported a net margin of 72.96% and quarterly revenue of $1.53 billion, exceeding analyst estimates.
• Multiple analysts have upgraded Edwards Lifesciences' stock, with price targets ranging from $81.00 to $86.26 and a consensus rating of "Moderate Buy."

Intech Investment Management LLC reduced its holdings in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 54.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 77,244 shares of the medical research company's stock after selling 93,151 shares during the period. Intech Investment Management LLC's holdings in Edwards Lifesciences were worth $5,599,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in EW. Brighton Jones LLC purchased a new position in Edwards Lifesciences during the fourth quarter valued at $266,000. Bank Pictet & Cie Europe AG lifted its holdings in Edwards Lifesciences by 16.7% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 10,231 shares of the medical research company's stock valued at $757,000 after purchasing an additional 1,463 shares in the last quarter. Focus Partners Wealth lifted its holdings in Edwards Lifesciences by 43.9% during the fourth quarter. Focus Partners Wealth now owns 63,380 shares of the medical research company's stock valued at $5,089,000 after purchasing an additional 19,347 shares in the last quarter. Gotham Asset Management LLC lifted its holdings in Edwards Lifesciences by 105.8% during the fourth quarter. Gotham Asset Management LLC now owns 16,423 shares of the medical research company's stock valued at $1,216,000 after purchasing an additional 8,444 shares in the last quarter. Finally, NorthRock Partners LLC lifted its holdings in Edwards Lifesciences by 102.7% during the fourth quarter. NorthRock Partners LLC now owns 20,097 shares of the medical research company's stock valued at $1,488,000 after purchasing an additional 10,183 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares of the company's stock, valued at $1,748,278.92. The trade was a 15.75% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction on Monday, June 16th. The shares were sold at an average price of $75.23, for a total transaction of $673,308.50. Following the completion of the transaction, the insider directly owned 206,900 shares in the company, valued at $15,565,087. The trade was a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 22,014 shares of company stock valued at $1,698,844 in the last quarter. 0.34% of the stock is owned by insiders.

Edwards Lifesciences Trading Down 0.7%

Edwards Lifesciences stock traded down $0.51 during midday trading on Friday, hitting $77.50. 6,301,589 shares of the stock were exchanged, compared to its average volume of 3,779,818. Edwards Lifesciences Corporation has a fifty-two week low of $64.00 and a fifty-two week high of $83.00. The stock has a market capitalization of $45.50 billion, a price-to-earnings ratio of 11.15, a PEG ratio of 3.74 and a beta of 1.07. The stock's 50-day simple moving average is $78.92 and its 200 day simple moving average is $75.42. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.05. The firm had revenue of $1.53 billion during the quarter, compared to analysts' expectations of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. Edwards Lifesciences's revenue was up 11.9% compared to the same quarter last year. During the same period last year, the business earned $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, equities analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Analyst Ratings Changes

Several research firms have issued reports on EW. Truist Financial increased their price objective on shares of Edwards Lifesciences from $81.00 to $82.00 and gave the company a "hold" rating in a report on Friday, July 25th. Morgan Stanley increased their price objective on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company an "equal weight" rating in a report on Tuesday, July 15th. Evercore ISI increased their target price on shares of Edwards Lifesciences from $77.00 to $80.00 and gave the company an "in-line" rating in a research report on Friday, July 25th. Royal Bank Of Canada increased their target price on shares of Edwards Lifesciences from $85.00 to $89.00 and gave the company an "outperform" rating in a research report on Friday, July 25th. Finally, Mizuho increased their target price on shares of Edwards Lifesciences from $87.00 to $95.00 and gave the company an "outperform" rating in a research report on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Edwards Lifesciences has a consensus rating of "Moderate Buy" and an average price target of $86.26.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.